gdc
CLL Monthly Minutes

CLL Monthly Minutes

CLL Monthly MinutesLeukemia
A federal law protects consumers from receiving bills covering the balance of many out-of-network emergency medical services.
CLL Monthly MinutesLeukemia
Combined acalabrutinib, venetoclax, and obinutuzumab have shown favorable efficacy and tolerability in untreated patients in an ongoing phase 2 study.
CLL Monthly MinutesLeukemia
The need to protect patients and healthcare workers from contracting COVID-19 has resulted in many changes to how hospital care is delivered.
CLL Monthly MinutesLeukemia
Recent data suggest that patients with CLL who received treatment with a BTK inhibitor had a rate of developing a second cancer over twice as high as that expected in the general population.
CLL Monthly MinutesLeukemia
Targeted therapies continue to change the treatment landscape, improving outcomes beyond traditional chemoimmunotherapy.
CLL Monthly MinutesLeukemia
Although most employers are not passing costs to employees, the COVID-19 pandemic has raised uncertainty throughout the entire healthcare system.
CLL Monthly MinutesLeukemia
An analysis of 4 studies finds that acalabrutinib does not increase the risk of developing heart problems for patients with CLL.
CLL Monthly MinutesLeukemia
A 5-year analysis of the MURANO study shows patients completing venetoclax treatment have long-term, durable responses.
CLL Monthly MinutesLeukemia
A systematic review of publications finds that patients with hematologic cancers who contract COVID-19 have an increased risk of death.
Page 2 of 2
Results 11 - 19 of 19

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country